Re: SUCCINCT: An Open-Label, Single-Arm, Non-Randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-Line Treatment for Patients with Advanced Urothelial Carcinoma Editorial Comment

Chang Sam S.

首页> 外文期刊>The Journal of Urology >Re: SUCCINCT: An Open-Label, Single-Arm, Non-Randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-Line Treatment for Patients with Advanced Urothelial Carcinoma Editorial Comment

【24h】

Re: SUCCINCT: An Open-Label, Single-Arm, Non-Randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-Line Treatment for Patients with Advanced Urothelial Carcinoma Editorial Comment

机译：回复：SUCCINCT：吉西他滨和顺铂化疗联合舒尼替尼作为晚期尿道上皮癌患者的一线治疗的开放标签，单臂，非随机化，2期试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Journal of Urology》 |2015年第6期|共2页
作者
Chang Sam S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献

1. Re: SUCCINCT: An Open-Label, Single-Arm, Non-Randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-Line Treatment for Patients with Advanced Urothelial Carcinoma Editorial Comment [J] . Chang Sam S. The Journal of Urology . 2015,第6期

机译：回复：SUCCINCT：吉西他滨和顺铂化疗联合舒尼替尼作为晚期尿道上皮癌患者的一线治疗的开放标签，单臂，非随机化，2期试验
2. SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma [J] . Geldart Thomas, Chester John, Casbard Angela, European urology . 2015,第4期

机译：SUCCINCT：吉西他滨联合顺铂化疗联合舒尼替尼作为一线治疗单药，单臂，非随机，2期临床试验，用于晚期尿路上皮癌患者
3. SUCCINCT: An open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma [J] . Thomas Geldart, John Chester, Tony Elliott, Indian heart journal . 2015,第4期

机译：简洁：吉西他滨和顺铂化疗的开放标签，单臂，非随机化，相2试验与Sunitinib为先进的尿路上皮癌患者的一线治疗
4. Efficacy of Intraperitoneal Perfusion Hyperthermic Chemotheraphy(CHIP)With Cisplatin Combined With Intraveuous Chemotherapy for Patients With Advanced Gastrointestinal Carcinoma [C] . The 3rd Asian congress on hyperthermic oncology and the 9th Chineses symposium on hyperthermic oncology . 2002

机译：腹腔灌注热化学疗法（CHIP）联合顺铂联合静脉化疗治疗晚期胃肠道癌的疗效
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. SUCCINCT: An Open-label Single-arm Non-randomised Phase 2 Trial ofGemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-lineTreatment for Patients with Advanced Urothelial Carcinoma [O] . Thomas Geldart, John Chester, Angela Casbard, -1

机译：SUCCINCT：一项开放标签单臂非随机2期试验吉西他滨和顺铂联合舒尼替尼作为一线化疗晚期尿路上皮癌的治疗
7. SUCCINCT: An open-label, single-arm, non-randomised, Phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma [O] . Geldart, Thomas, Chester, John D., Casbard, Angela C., 2015

机译：SUCCINCT：吉西他滨和顺铂化疗联合舒尼替尼作为晚期尿路上皮癌患者的一线治疗的开放标签，单臂，非随机，2期临床试验

Re: SUCCINCT: An Open-Label, Single-Arm, Non-Randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-Line Treatment for Patients with Advanced Urothelial Carcinoma Editorial Comment

著录项

相似文献

相关主题

期刊订阅